A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
Glucagon-like peptide-1 (GLP-1) receptor agonists, commonly used for glycemic control in patients with type 2 diabetes and for weight loss in obese patients, have been increasingly used due to their effectiveness in treating these conditions and in r…
BACKGROUND: Oral semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), has been shown to reduce major adverse cardiovascular events (MACE) in high-risk individuals with type 2 diabetes in the SOUL trial. Its potential population-level i…
AIMS: Oral semaglutide absorption is subject to inter-individual variability. We investigated whether estimated individual exposure (eC) provides predictive information beyond the prescribed dose in a real-world cohort of patients with type 2 diabete…
BACKGROUND: While the FLOW trial established the renoprotective effects of subcutaneous semaglutide, real-world evidence regarding the long-term renal effects of therapeutic switching from injectable glucagon-like peptide-1 receptor agonists (GLP-1RA…
PURPOSE: To evaluate the association of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) use on macrovascular and microvascular outcomes in patients with type 2 diabetes (T2D) and diabetic retinopathy (DR)-a high-risk group often excluded from c…
AIMS: Atrial fibrillation (AF) is strongly associated with adverse outcomes, particularly in patients with heart failure (HF). AF susceptibility is driven by atrial remodelling, including electrical disarray, inflammation, and fibrosis, yet current t…
OBJECTIVE: Semaglutide improves cardiovascular disease (CVD) risk in people who are diabetic, overweight or obese through incompletely understood mechanisms. To address this, we explored novel lipidomic and lipo-/glyco-protein profiling with semaglut…
Metabolic dysfunction-associated steatohepatitis (MASH), the progressive form of metabolic dysfunction-associated steatotic liver disease (MASLD), has historically been treated with lifestyle modification (dietary changes, exercise and weight loss).…
Glucagon-Like Peptide-1 (GLP-1) receptor agonists are widely used to manage type 2 diabetes and promote weight loss. Semaglutide (SEM)-a long acting GLP-1-has experienced an extraordinary surge in popularity since its approval in 2017. Between 2021 a…
BACKGROUND: Abdominoplasty in patients with obesity carries a heightened risk of venous thromboembolism (VTE) due to a proinflammatory and hypercoagulable baseline. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for weigh…
OBJECTIVE: Semaglutide (SMG), a clinically relevant peptide-based therapeutic whose physical and chemical stability are critical concerns during manufacturing and storage. Although the stability of SMG in solution has been extensively studied, its so…
OBJECTIVES: To investigate the clinical characteristics of weight loss drugs (WLDs) users in Norway. DESIGN: Nested population-based case-control study. SETTING: Nationwide healthcare registries with data on dispensed medications and healthcare diagn…
The introduction of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual incretin agonists targeting both the GIP and GLP-1 receptors (GIP/GLP-1 dual agonists) has reshaped obesity management, approaching degrees of weight loss previously a…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) like semaglutide are well-used for type 2 diabetes and obesity, and recent studies show their potential renal benefits in both diabetic and non-diabetic people. However, evidence for s…
BACKGROUND AND OBJECTIVES: Recent observational studies have reported conflicting evidence regarding an association between glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly semaglutide, and nonarteritic anterior ischemic optic neuro…
The rapid proliferation of anti-obesity medications (AOMs), including glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agonist tirzepatide, and non-incretin agents, including orl…
Emerging research suggests a potential role for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in alcohol use disorder (AUD), because GLP-1 receptors are present in the brain regions involved in dopamine signaling and the human reward system.…
INTRODUCTION: As glucagon-like peptide-1 receptor agonist (GLP-1) use has increased among children, a better understanding of the related adverse effects in this population is needed. METHODS: National Poison Data System data from 2017 to 2024 were a…